Malaria Clinical Trial
Official title:
Safety and Immunogenicity of ChAd63 ME-TRAP / MVA ME-TRAP Heterologous Prime Boost Malaria Vaccination Adjuvanted With Matrix M™
ChAd63 METRAP and MVA METRAP are investigational vaccines for malaria which have been
studied in clinical trials for 4 years, and 10 years, respectively. These vaccines are
inactivated viruses which have been modified so that they cannot reproduce in humans.
Genetic information has been added to make them express proteins of the malaria parasite so
that they stimulate an immune response against malaria. This trial examines whether a
compound called Matrix M™ can be used in efforts to improve on how well the vaccines work at
preventing malaria.
Matrix M™ is a vaccine adjuvant, a compound used to improve the immune responses to
vaccines. In this trial, Matrix M™ will be combined with each of the vaccines. The
objectives are to assess the safety of the vaccines when combined with Matrix M™, and to
determine what effect Matrix M™ has on the immune responses to the vaccines.
We will assess the safety of the vaccines (ChAd63 METRAP combined with Matrix M™; and MVA
METRAP combined with Matrix M™) by administering them to healthy volunteers and monitoring
them for 6 months in total. Eight volunteers will receive the vaccines with the low dose of
Matrix M™, eight will receive the vaccines with the standard dose of Matrix M™, and six
volunteers will receive the vaccines alone as a comparison group. We will also look at what
effect Matrix M™ has on the immune responses to the vaccines, as measured from blood tests.
Volunteers will have study visits to the Clinical Centre for Vaccinology and Tropical
Medicine on the Churchill Hospital site, Oxford, where they will have vaccinations, have
blood taken to monitor safety and measure immune responses to vaccination, and be monitored
for symptoms/side effects from vaccination.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |